Clinical trials: GnRH Antagonist
Infertility and at High Risk of OHSS
Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022241
- Testing
- triptorelin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chenshiling
Infertility
Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs.
- Trial name
- Gonapeptyl (NCT01468441)
- Testing
- Triptorelin, Cetrorelix
- Where
- Brazil
- Volunteers
- 96 people
- Sponsor
- Fertility - Assisted Fertilization Center
Infertility
Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients.
- Trial name
- NCT00823602
- Testing
- ganirelix, suprefact
- Where
- Iran
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Yazd Research & Clinical Center for Infertility
Ovarian Stimulation
Antagonist/Letrozole in Poor Responders
Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders.
- Trial name
- NCT00823004
- Testing
- letrozole, oral contraceptive (Marvelone), GnRH agonist (buserelin)
- Where
- Iran
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yazd Research & Clinical Center for Infertility
Prostate Cancer
Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Androgen deprivation therapy (ADT) is considered standard of care for prostate cancer. However, changes in the patients metabolism are usually seen as a result of hormone therapy.
- Trial name
- NCT01226888
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Controlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
The purpose of this study is to compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved…
- Trial name
- NCT06812559
- Testing
- Progesterone, GnRH antagonist (Cetrorelix)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- El Shatby University Hospital for Obstetrics and Gynecology
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Infertility and at High Risk of OHSS
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022228
- Testing
- triptorelin, hCG
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chenshiling
Infertility
A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment
This is a multicenter retrospective study in good prognosis Chinese patients. Data will be collected from infertile women who underwent first in vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI) using a…
- Trial name
- FASSION (NCT02889380)
- Testing
- No Intervention
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT)…
- Trial name
- PRONOUNCE (NCT02663908)
- Testing
- Degarelix, Leuprolide
- Where
- 133 sites in United States, Canada and 10 more
- Volunteers
- 545 people
- Sponsor
- Ferring Pharmaceuticals
Infertility
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
This is a multicentric, prospective, observational study on the use of Cetrotide to control the endogenous gonadotrophin levels in Gonal-f stimulated ART treatment cycles in the Asia-Pacific region.
- Trial name
- NCT01109654
- Testing
- Cetrorelix acetate and Follitropin alfa
- Where
- Singapore
- Volunteers
- 2,175 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Infertility, Female
GnRh Antagonist Protocol With Delayed Start Stimulation in Patients With Poor Ovarian Response
The main outcome measures are the number of dominant follicles (≥13 mm) on the day of hCG trigger and the number of mature (MII) oocytes collected after conventional versus delayed-start ovarian stimulation protocol.
- Trial name
- NCT03134690
- Testing
- delayed start, Conventional
- Where
- Iran
- Volunteers
- 120 people
- Sponsor
- Royan Institute
Infertility
Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.
- Trial name
- NCT01419353
- Testing
- estradiol valerate
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Infertility, IVF Treatment
Early Follicular Supplementation of Ganirelix in IVF 2004
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
- Trial name
- NCT00461422
- Testing
- Ganirelix
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- The Baruch Padeh Medical Center, Poriya
Ovarian Function, Preservation of Ovarian Function
Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy
This study will examine whether the drug cetrorelex acetate (Cetrotide[Registed Trademark]) can protect ovarian function in women undergoing chemotherapy.
- Trial name
- NCT00507780
- Testing
- GnRH antagonist
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)